Commercial Due Diligence for CRO Investments

Industry knowledge-driven insight
to protect capital, valuation discipline,
and milestone credibility

In CRO investing, spreadsheets don’t kill returns. Assumptions do.
ILIKOS supports venture capital and growth investors by providing
commercial due diligence built specifically for service provider business models in the clinical research industry. We stress-test pipeline
credibility, revenue durability, and scalability so you can price risk
properly, structure smarter terms, avoid post-close surprises and
project ROI more accurately..

Book a diligence call
Request a sample IC memo outline

Outcomes Investors Care About

Our solutions are designed to change what happens in your deal
process, not add another workstream.

  • By the end of the engagement, you should be able to:
  • Defend valuation using conversion reality, not optimistic
    pipeline math
    Identify hidden downside before signing
  • Pressure-test growth milestones for credibility and achievability
  • Structure terms intelligently (milestones, tranches, triggers,
    downside protection) based on real risk
  • Enter IC with clarity and reduce debate driven by uncertainty

Trust Signals

  • Built by clinical research, commercial, and operational
    experts, not generic diligence teams
  • Outputs are investment committee-ready and designed
    for decision-making
  • Deal-timeline friendly, with structured intake and
    focused data requests
  • Complements financial and legal diligence by validating
    future revenue engines

Why Traditional Due Diligence Misses Service Provider Reality

Traditional financial diligence can confirm what the numbers say. It rarely confirms
whether those numbers can be repeated.

Many diligence providers approach service providers with a banking
lens: historical revenue, headline growth, and “stable clients.” In a
sector this volatile, that can be a costly blind spot. Service Provider
performance is driven by pipeline governance, sponsor behaviour,
business development methodology, delivery constraints, regulatory
landscape, development trends and emerging regions – factors that
determine whether revenue holds when conditions tighten.
ILIKOS evaluates service providers through an industry-expert commercial lens, designed to surface real risk before capital is committed.

Why Service Provider Underwriting Is Different

In the clinical research industry, service providers are not simple SaaS
businesses and not traditional services firms. Value is created at the
intersection of study sponsor behaviour, pipeline discipline, delivery
capacity, commercial execution and key external elements such as
regulatory landscape, development trends and the ability to expand
to emerging regions.
Investments in the clinical research industry tend to break when:
ILIKOS helps you separate signal from noise and convert findings into
deal leverage.
Pipeline stages are inflated, inconsistent, or not governed
Growth depends on one or two rainmakers rather than
a repeatable engine
Revenue stability is actually sponsor concentration
Forecasting collapses under normal market tightening
Delivery constraints turn growth into margin compression
and quality risk

ILIKOS helps you separate signal from noise and convert findings into
deal leverage.

What This Service Does for Your Deal

This is not a report.
It is an underwriting tool.

You use our findings to:

  • Validate whether the pipeline can support your growth narrative
    and milestones
  • Reprice forward revenue assumptions based on conversion reality
  • Adjust structure using tranches, milestones, downside protection,
    or performance triggers
    Identify what must be upgraded post-close in BD, pipeline
    governance, and account management
  • Avoid overpaying for performance that was timing-driven rather
    than capability-driven

What we Assess

Pipelines are promises, not assets. We test credibility the way operators do:

  • Stage definitions, governance, and consistency
  • Conversion rates by stage, sponsor type, and service line
  • Time-to-close and deal velocity trends
  • Average contract value and contract value distribution in relation to growth objectives
  • Pipeline diversity across sponsors, therapeutic areas, geographies, and service lines
  • Backlog vs pipeline vs awarded work definitions
  • Historical project mix: types of studies/services won, sponsor types, and what that implies for repeatability, pricing power, and margins
  • Deal source and pipeline diversity

We assess whether revenue is defensible and what it depends on:

  • Type of client and sponsor concentration risk
  • Revenue split between new and existing clients and what it signals about retention and expansion
  • Revenue by sponsor type, therapeutic area, and service line
  • Contract structures, pricing discipline, and change order practices
  • Revenue recognition practices and timing risk
  • Exposure to sponsor budget cycles and program volatility

We validate whether growth is driven by robust methodology or favorable industry dynamics: :

  • Lead sourcing model and RFP dependency vs proactive sourcing
  • Sales process maturity, governance, and performance tracking
  • CRM discipline and forecasting reliability
  • Key-person dependency across BD leadership and key accounts
  • Evidence of repeatable win mechanics vs opportunistic wins
  • Winability by project type assessment

We make account management tangible :

  • Client retention dynamics and rebid exposure
  • Expansion motion: cross-sell and upsell mechanics, not just intent
  • Account governance: renewal discipline, stakeholder mapping, QBR cadence, escalation paths
  • Sponsor relationship depth and continuity beyond one relationship holder
  • Signals of account health that predict renewals and expansions

We stress-test whether growth is operationally feasible:

  • Capacity vs pipeline commitments
  • Hiring constraints and resourcing elasticity
  • Subcontractor reliance and delivery bottlenecks
  • Margin leakage from scope creep, weak change order control, and delivery variability
  • Ability to scale without degrading quality, timelines, or sponsor experience

We test what happens when conditions tighten:

  • Sensitivity to pipeline slowdown and sponsor pullbacks
  • Forecast resilience under conservative scenarios
  • Failure modes that typically appear after closing

How it Works

Commercial Stress Test

We back-test and validate assumptions:

  • Conversion and velocity analysis
  • Pipeline governance and credibility
    scoring
  • Revenue durability and concentration
    risk mapping
  • Key-person dependency analysis
  • Scalability constraints and margin risk
    assessment

Commercial Stress Test

We back-test and validate assumptions:

  • Conversion and velocity analysis
  • Pipeline governance and credibility
    scoring
  • Revenue durability and concentration
    risk mapping
  • Key-person dependency analysis
  • Scalability constraints and margin risk
    assessment

Commercial Stress Test

We back-test and validate assumptions:

  • Conversion and velocity analysis
  • Pipeline governance and credibility
    scoring
  • Revenue durability and concentration
    risk mapping
  • Key-person dependency analysis
  • Scalability constraints and margin risk
    assessment

Engagement Options


Choose the level of depth based
on deal stage and urgency.

Option 1 :

Rapid Commercial Assessment

Best for early screening, pre-IC, or when deal velocity is high.
Focus: top risks, pipeline credibility, concentration exposure, and immediate valuation pressure points.